Peer Review History
| Original SubmissionApril 26, 2021 |
|---|
|
PONE-D-21-13777MOOD DISORDERS IN CHILDREN FOLLOWING NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHYPLOS ONE Dear Dr. Martínez-Orgado, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The reviewers agree that it is a professionally written article that adds new knowledge; therefore, they recommend its publication. However, they do make several suggestions that must be followed. Additionally, in the statistical analysis, I would like the effect size to be included. Please submit your revised manuscript by December 16, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Thalia Fernandez, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. 3. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This manuscript is professionally written. It describes the possible presence of Mood Disorders (MD) in a group of 14 children between 3- and six-year-old that at birth present Hypoxic Ischemic Encepalopathy (HIE) from moderate to severe (the scale values of Sarnat and Sarnat scores are not described) that were treated with hypothermia and without cerebral palsy and 15 healthy children without perinatal complications matched by gestational age, socioeconomic status, parental educational level, or monthly income. Infants had 35 weeks of gestational age or more. I will recommend the authors to include more clearly the number of preterm and term infants in the study, since the mean age in both groups was 38 weeks. The study used well known questionnaires to the parents, the Ages and Stages Questionnaire 3 (ASQ-3), the Child Behavior Checklist (CBCL) for children aged one and a half to five years, and the Montgomery-Asberg Depression Rating Scale (MADRS). Children completed the Preschool Symptom Self-Report (PRESS), a 143 pictorial instrument that assesses, with self-informed responses from identification with 144 images, the presence of depression symptoms in preschool children. Unfortunately, in the abstract only the acronyms of the tests are used. My recommendation is to use the complete title of the tests also in the abstract. This is mandatory. Magnetic Resonance Images (MRI) were obtained from the children early after birth and at the age of two to three years. Authors only described the results of the images, but not include any figure. I think that the presentation of the images of the child with a lesion at birth and that was normal after 3 years will be welcome. The authors only describe MRI studies of the HIE group. To have a perfect mismatch with the HIE children, studies of the healthy children should be also included. It has been shown by MRI (Rutherford et al., 2010) that hypothermia treatment of infants with HIE decreases brain injury tissues, therefore should be interesting to know the MRI results of the control group. In case of preterm infants frequent MRI abnormalities have been described (Volpe, J in 2011, 2019; Woodward et al. 2012; and Harmony, 2021). Conclusion: I recommend the authors to follow my suggestions. Reviewer #2: Dear Editor and the authors, Thank you for the opportunity to review the report about mood disorders in children with hypoxic-ischemic encephalopathy (HIE). The report is well written and worth publication, even it is a descriptive study because of the paucity of knowledge about emotional developments of infants after neonatal HIE. It adds new knowledge and is worth publication. However, there are some limitations of study, which have not been discussed. I will specify it below. First, I will address the statistical analysis and presentation of the results. The authors have chosen the right method for the analyses (Mann-Whitney U test) because of skewed distribution of data. Therefore, results should be presented by medians instead of means. The study was well planned, with two different sources of data regarding mood disorders (CBCL and PRESS) and a control group. I will also commend the authors for including the most important environmental factors (education level, income and parental depressive symptoms). Unfortunately, the assessors were not blinded. I fully understand that it is difficult to blind the assessors in a clinical setting, but I really miss discussion how not-blinded evaluation of the outcome affects the results. Line 69-71. The authors state that emotional consequences of disability of CP can mask the effects of NHIE by itself. I totally agree. Later, when the authors cite the same study in the discussion, Line 281, they interpret results differently than the authors of the cited study. Rackauskaite et al. wrote “the high prevalence of psychopathology in children with CP may be due to brain impairment or cognitive disability and not to the motor disability itself”. Please, correct it. Line 160-164 presents data from the Figure 1. There is no need for repetition. Line 182/ Table 1. There is a difference of 6 months between the mean age of control and NHIE. Emotional development is quite fast between the age of 4½ and 4 years. Please, discuss if that can influence your results, even the ages are not statistically significant. Line 238 is difficult to read. Please, rephrase. Line 270-275 repeats information from the introduction. Line 332-334. Handicap is a strong word in the context of HNIE. I suggest to reword “could be a handicap” by using a verb like “could disturb” or “interfere with”. Line 341-342. Your data does not support the statement, that MD were not related to the severity of handicap. All children (HNIE and controls) had a normal motor and cognitive function, thereby no handicap. I hope my suggestions will help the authors to improve their report. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Thalía Harmony Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
MOOD DISORDERS IN CHILDREN FOLLOWING NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY PONE-D-21-13777R1 Dear Dr. Martinez-Orgado, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Thalia Fernandez, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-21-13777R1 Mood Disorders in Children following Neonatal Hypoxic-Ischemic Encephalopathy Dear Dr. Martínez-Orgado: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Thalia Fernandez Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .